



US009511096B2

(12) **United States Patent**
Fraser et al.

(10) **Patent No.:** **US 9,511,096 B2**
(45) **Date of Patent:** ***Dec. 6, 2016**

(54) **METHODS OF USING REGENERATIVE CELLS TO TREAT AN ISCHEMIC WOUND**

(71) Applicant: **CYTORI THERAPEUTICS, INC.**,
San Diego, CA (US)

(72) Inventors: **John K. Fraser**, San Diego, CA (US);
Marc H. Hedrick, Encinitas, CA (US);
Eric Daniels, Encinitas, CA (US)

(73) Assignee: **Cytori Therapeutics, Inc.**, San Diego,
CA (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 331 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **14/180,553**

(22) Filed: **Feb. 14, 2014**

(65) **Prior Publication Data**

US 2014/0227234 A1 Aug. 14, 2014

Related U.S. Application Data

(60) Division of application No. 13/360,022, filed on Jan.
27, 2012, now Pat. No. 8,691,216, which is a division
of application No. 10/884,860, filed on Jul. 1, 2004,
now Pat. No. 8,105,580, which is a
continuation-in-part of application No. 10/316,127,
filed on Dec. 9, 2002, now abandoned.

(60) Provisional application No. 60/338,856, filed on Dec.
7, 2001.

(51) **Int. Cl.**

A61K 45/00 (2006.01)

A61K 35/28 (2015.01)

A61K 35/12 (2015.01)

C12N 5/0775 (2010.01)

C12N 5/071 (2010.01)

A61K 35/36 (2015.01)

A61K 35/44 (2015.01)

A61K 38/18 (2006.01)

A61K 45/06 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 35/28** (2013.01); **A61K 35/12**
(2013.01); **A61K 35/36** (2013.01); **A61K 35/44**
(2013.01); **A61K 38/1866** (2013.01); **A61K**
45/06 (2013.01); **C12N 5/069** (2013.01);
C12N 5/0667 (2013.01); **C12N 2506/1384**
(2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,917,515 A 11/1975 Goldberg
4,000,275 A 12/1976 Lunn

4,146,172 A 3/1979 Cullis et al.
4,418,691 A 12/1983 Yannas et al.
4,458,678 A 7/1984 Yannas et al.
4,466,888 A 8/1984 Verkaart
4,734,269 A 3/1988 Clarke et al.
4,820,626 A 4/1989 Williams et al.
4,834,703 A 5/1989 Dubrul et al.
4,883,755 A 11/1989 Carabasi et al.
4,897,185 A 1/1990 Schuyler et al.
4,963,489 A 10/1990 Naughton et al.
5,034,135 A 7/1991 Fischel
5,035,708 A 7/1991 Alchas et al.
5,079,160 A 1/1992 Lacy et al.
5,087,244 A 2/1992 Wolinsky et al.
5,092,883 A 3/1992 Eppley et al.
5,131,907 A 7/1992 Williams et al.
5,143,063 A 9/1992 Fellner
5,158,867 A 10/1992 McNally et al.
5,226,914 A 7/1993 Caplan et al.
5,234,608 A 8/1993 Duff
5,261,612 A 11/1993 Ftaiha
5,312,380 A 5/1994 Alchas et al.
5,372,945 A 12/1994 Alchas et al.
5,409,833 A 4/1995 Hu et al.
5,436,135 A 7/1995 Tayot et al.
5,470,307 A 11/1995 Lindall
5,486,359 A 1/1996 Caplan et al.
5,521,087 A 5/1996 Lee et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 1287166 3/2001
CN 101258237 9/2008

(Continued)

OTHER PUBLICATIONS

Abbate, A., Biondi-Zoccai, G.G. and Baldi, A. (2002) "Pathophysi-
ologic role of myocardial apoptosis in post-infarction left ventricu-
lar remodeling" *J Cell Physiol* 193, 145-53.

Aharinejad, S., Mars, S.C., Jr., Bock P., Mason-Savas, A., MacKay,
C.A. Larson, E.K., Jackson, M.E., Luftensteiner, M. and Weisbauer,
E. (1995) "CSF-1 treatment promotes angiogenesis in the meta-
physics of osteopetrotic (toothless, tl) rats" *Bone* 16, 315-324.

Ahrens, Patricia Buckley et al., "Stage-Related Capacity for Limb
Chondrogenesis in Cell Culture," *Developmental Biology*, 1977,
60:69-82.

(Continued)

Primary Examiner — Blaine Lankford

(74) *Attorney, Agent, or Firm* — Knobbe Martens Olson
& Bear LLP

(57) **ABSTRACT**

Cells present in adipose tissue are used to promote wound
healing in a patient. Methods of treating patients include
processing adipose tissue to deliver a concentrated amount
of regenerative cells obtained from the adipose tissue to a
patient. The methods may be practiced in a closed system so
that the regenerative cells are not exposed to an external
environment prior to being administered to a patient.
Accordingly, in a preferred method, cells present in adipose
tissue are placed directly into a recipient along with such
additives necessary to promote, engender or support a thera-
peutic benefit.

25 Claims, 22 Drawing Sheets